Literature DB >> 34510556

A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis.

K Hansel1, A Zangrilli2, L Bianchi1, K Peris3, A Chiricozzi3, A Offidani4, F Diotallevi4, M C Fargnoli5, M Esposito5, P Amerio6, G Gualdi6, L Bianchi1, L Stingeni1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34510556     DOI： 10.1111/jdv.17656

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  5 in total

1.  Risankizumab shows high efficacy and maintenance in improvement of response until week 52.

Authors:  Luca Mastorino; Sara Susca; Matteo Megna; Niccolò Siliquini; Pietro Quaglino; Michela Ortoncelli; Gianluca Avallone; Marco Rubatto; Gabriella Fabbrocini; Paolo Dapavo; Simone Ribero
Journal:  Dermatol Ther       Date:  2022-02-28       Impact factor: 3.858

2.  Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.

Authors:  Giacomo Caldarola; Arianna Zangrilli; Nicoletta Bernardini; Mauro Bavetta; Clara De Simone; Dario Graceffa; Claudio Bonifati; Sara Faleri; Domenico Giordano; Marco Mariani; Adriana Micheli; Gaia Moretta; Gianluca Pagnanelli; Vincenzo Panasiti; Alessia Provini; Antonio Richetta; Ketty Peris; Luca Bianchi
Journal:  Dermatol Ther       Date:  2022-04-13       Impact factor: 3.858

3.  Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials.

Authors:  Mark G Lebwohl; Ahmed M Soliman; Hongbo Yang; Jessie Wang; Kaitlin Hagan; Byron Padilla; Andreas Pinter
Journal:  Dermatol Ther (Heidelb)       Date:  2021-12-18

Review 4.  Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.

Authors:  Angelo Ruggiero; Vincenzo Picone; Fabrizio Martora; Gabriella Fabbrocini; Matteo Megna
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-16

5.  Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study.

Authors:  Luigi Gargiulo; Luciano Ibba; Giulia Pavia; Carlo Alberto Vignoli; Francesco Piscazzi; Mario Valenti; Federica Sanna; Chiara Perugini; Jessica Avagliano; Antonio Costanzo; Alessandra Narcisi
Journal:  Dermatol Ther (Heidelb)       Date:  2022-09-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.